{
  "ar_aging": {
    "total_ar": 4484283,
    "current_0_30": 4269558,
    "current_pct": 95.2,
    "aging_31_60": 80109,
    "aging_61_90": 24918,
    "aging_over_90": 109698,
    "at_risk_total": 134616,
    "at_risk_pct": 3.0,
    "customer_count": 127,
    "high_risk_customers": 16,
    "status": "HEALTHY"
  },
  "cash_position": {
    "cash_balance": 3001055,
    "total_ar": 4484283,
    "total_ap": 0,
    "net_working_capital": 7485338,
    "quick_ratio": 999,
    "dso_days": 0.1,
    "dpo_days": 40,
    "cash_conversion_cycle": -39.9,
    "liquidity_status": "HEALTHY"
  },
  "high_risk_ar_customers": [
    {"name": "LivaNova USA", "over_90": 46400, "total_at_risk": 46400},
    {"name": "Direct Biologics", "over_90": 24494, "total_at_risk": 24494},
    {"name": "Verax Biomedical", "over_90": 16570, "total_at_risk": 16570},
    {"name": "Axsome Therapeutics", "over_90": 11089, "total_at_risk": 11089},
    {"name": "Lyra Therapeutics", "aging_61_90": 9000, "total_at_risk": 9000},
    {"name": "Enovis Corporation", "aging_61_90": 7658, "total_at_risk": 7658}
  ],
  "insights": [
    "AR health is excellent - 95.2% current, only 3% at risk",
    "Strong cash position of $3M with $7.5M net working capital",
    "Enovis (problem margin customer) also has AR aging issues - $7.7K in 61-90 days",
    "LivaNova is biggest AR risk at $46K over 90 days"
  ],
  "generated_at": "2026-02-03T06:30:00Z"
}
